Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS
T. V. Korotaeva,
O. A. Pritulo,
O. B. Nesmeyanova,
O. R. Ziganshin,
L. L. Rusakova,
E. S. Zhugrova,
I. M. Marusenko,
O. N. Mironenko https://doi.org/10.14412/1996-7012-2025-4-32-39
Abstract
Objective: to evaluate the efficacy, safety, and treatment persistence of netakimab (NTK) in patients with active psoriatic arthritis (PsA) in realworld clinical practice at 52 weeks of follow-up.
Material and methods. This observational prospective cohort study included 149 patients with active PsA receiving NTK treatment in accordance with clinical guidelines. As of the data cut-off (April 21, 2025), the median follow-up duration was 63 weeks (range: 22–117 weeks). The primary endpoint was treatment persistence with NTK. Safety and tolerability were assessed through the documentation of adverse events (AEs).
Results and discussion. By week 52, treatment persistence with NTK reached 96.0%. At the time of analysis, 12 (8.1%) out of 149 patients had discontinued NTK, with lack of efficacy reported in 9 cases. By week 52, only 2 AEs had been recorded, and just 1 was considered related to NTK.
Conclusion. Over the 1-year observation period, NTK demonstrated a high treatment persistence rate, efficacy, and an acceptable safety profile in patients with PsA in real-world clinical practice.
About the Authors
T. V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Tatyana Viktorovna Korotaeva, MD, PhD, Head of the Department of Spondyloarthritis, Head of the Laboratory of Psoriatic Arthritis,
34A, Kashirskoye Shosse, Moscow 115522
O. A. Pritulo
V.I. Vernadsky Crimean Federal University
Russian Federation
Russian Federation
4, Akademika Vernadskogo Avenue, Simferopol 295007
O. B. Nesmeyanova
Chelyabinsk Regional Clinical Hospital
Russian Federation
Russian Federation
70, Vorovskogo Street, Chelyabinsk 454048
O. R. Ziganshin
Chelyabinsk Regional Dermatovenerologic Dispensary
Russian Federation
Russian Federation
24, Yablochkina Street, Chelyabinsk 454048
L. L. Rusakova
Bryansk Regional Dispensary of Dermatology and Venereology
Russian Federation
Russian Federation
2, Aviatsionny Lane, Bryansk 241001
E. S. Zhugrova
“Medical Unit No. 157” LLC
Russian Federation
Russian Federation
100A, Varshavskaya Street, St. Petersburg 196066
I. M. Marusenko
Petrozavodsk State University
Russian Federation
Russian Federation
33, Lenina Avenue, Petrozavodsk 185910
O. N. Mironenko
Russian Presidential Academy of National Economy and Public Administration
Russian Federation
Russian Federation
82, Vernadskogo Avenue, Build. 1, Moscow 119571
Review
For citations:
Korotaeva TV, Pritulo OA, Nesmeyanova OB, Ziganshin OR, Rusakova LL, Zhugrova ES, Marusenko IM, Mironenko ON. Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(4):32-39. (In Russ.) https://doi.org/10.14412/1996-7012-2025-4-32-39
Views:
23
Email this article 